BAALC

BAALC encodes a small, membrane-associated cytoplasmic scaffold/adaptor protein whose stage-restricted expression marks CD34+ hematopoietic progenitors and is downregulated as cells commit to myeloid lineages (PMID:14585369). In neurons the 1-6-8 isoform is anchored to postsynaptic lipid rafts through N-terminal myristoylation and palmitoylation and binds the regulatory domain of CaMKIIα, establishing a raft-targeted adaptor function (PMID:15659234). In leukemia, BAALC functions as an oncogenic scaffold: it binds MEKK1 (MAP3K1) and blocks MKP3/DUSP6-mediated ERK dephosphorylation to sustain ERK activity, while simultaneously sequestering the transcription factor KLF4 in the cytoplasm to block monocytic differentiation, together driving cell-cycle progression and chemoresistance (PMID:26050649). It additionally signals through phosphorylation of MK2a (MAPKAPK2), and its loss selectively halts proliferation and induces differentiation of CN/AML blasts without affecting normal HSPCs (PMID:33894142), and it interacts with the actin-binding protein DBN1 to promote stromal adhesion and microenvironment-mediated chemoresistance (PMID:33453340). Functionally, BAALC promotes leukemia cell survival and proliferation, as knockdown reduces growth and increases apoptosis (PMID:22549446). Its transcription is activated by a RUNX1-binding promoter SNP and by an SP1/NF-κB complex, and is shaped by histone modifications consistent with a paused promoter state (PMID:22493267, PMID:24736457, PMID:22197554).

1. 2001 Low

   Establishing the basic cell biology of BAALC as a cytoplasmic protein with multiple isoforms was the first step toward assigning any function.

   Evidence Subcellular localization and genomic/splice-variant analysis in vitro

   PMID:11707601

   Open questions at the time

   • Localization inferred in vitro with no functional validation
   • Roles of individual isoforms undefined
   • No binding partners identified
2. 2003 Medium

   Defining where BAALC is normally expressed linked it to progenitor identity, framing why its dysregulation matters in leukemia.

   Evidence FACS sorting of bone marrow subpopulations with RT-PCR plus cytokine-driven differentiation assays

   PMID:14585369

   Open questions at the time

   • Expression pattern does not establish a causal function
   • Mechanism of downregulation upon differentiation unknown
3. 2005 High

   Identifying lipid-raft targeting via lipidation and a direct CaMKIIα interaction revealed BAALC as a membrane-anchored adaptor in neurons.

   Evidence Co-IP/pull-down, raft fractionation, and mutagenesis of myristoylation/palmitoylation sites in rat brain

   PMID:15659234

   Open questions at the time

   • Functional consequence of CaMKIIα binding for synapse physiology not resolved
   • Whether raft targeting applies to hematopoietic isoforms unknown
4. 2012 Medium

   Loss-of-function established BAALC as functionally required for leukemia cell survival rather than merely a marker.

   Evidence shRNA knockdown in KG1a AML cells with proliferation and apoptosis readouts

   PMID:22549446

   Open questions at the time

   • Single cell line
   • Molecular mechanism downstream of BAALC not addressed
5. 2012 High

   Discovery of a RUNX1-binding promoter SNP explained allele-specific transcriptional control of BAALC and connected it to a master hematopoietic regulator.

   Evidence Luciferase reporter and EMSA validated across two AML patient cohorts

   PMID:22493267

   Open questions at the time

   • Does not address post-transcriptional or epigenetic layers of regulation
6. 2014 Medium

   Mapping the SP1/NF-κB and RUNX1 inputs and the embedded miR-3151 clarified the shared and separable transcriptional control of the BAALC locus.

   Evidence Reporter assays, TF-binding studies, and miRNA gain/loss in cell lines and a mouse leukemogenesis model

   PMID:24736457

   Open questions at the time

   • Relative contribution of each TF in vivo unclear
   • Functional separation of miR-3151 vs BAALC effects incomplete
7. 2015 High

   Identifying the MEKK1 and KLF4 interactions provided the first molecular mechanism by which BAALC sustains ERK signaling and blocks differentiation.

   Evidence Reciprocal Co-IP, nuclear/cytoplasmic fractionation, ERK activity assays, and MEK inhibition in vitro and in vivo

   PMID:26050649

   Open questions at the time

   • Structural basis of MEKK1 and KLF4 binding not defined
   • How one scaffold coordinates both interactions unknown
8. 2020 Medium

   NMR backbone assignment provided the first structural foothold for an otherwise poorly characterized protein and showed isoforms share a similar backbone.

   Evidence Solution NMR backbone assignment of the 180-residue hematopoietic isoform 1

   PMID:32240523

   Open questions at the time

   • No folded domain or interaction interface determined
   • Functional mapping of structure to partner binding absent
9. 2021 High

   CRISPR deletion and phosphoproteomics pinpointed MK2a as a BAALC effector and demonstrated a leukemia-selective therapeutic vulnerability.

   Evidence CRISPR-Cas9 KO in iPSC-derived CN/AML HSPCs, phosphoproteomics, and CMPD1 inhibition in primary blasts

   PMID:33894142

   Open questions at the time

   • Direct biochemical link between BAALC and MK2a phosphorylation not shown
   • Relationship to the ERK/MEKK1 axis not integrated
10. 2021 Medium

    Identifying the DBN1 interaction connected BAALC to actin-dependent stromal adhesion and microenvironmental chemoresistance.

    Evidence Mass spectrometry interaction mapping with DBN1 knockdown adhesion and cytarabine sensitivity assays

    PMID:33453340

    Open questions at the time

    • Interaction not confirmed by reciprocal Co-IP
    • Direct vs indirect binding unresolved
11. 2021 Medium

    Reciprocal gain/loss-of-function in breast cancer cells extended BAALC's pro-tumorigenic scaffold role beyond hematopoiesis via FAK/MMP-9 signaling.

    Evidence Overexpression and siRNA knockdown in breast cancer lines with FAK inhibitor and gelatin zymography

    PMID:33968759

    Open questions at the time

    • Whether BAALC binds FAK directly not established
    • Generalizability across solid tumors unknown

• How a single small lipidated scaffold coordinates its distinct partner interactions (MEKK1, KLF4, DBN1, CaMKIIα) and links to MK2a phosphorylation at the structural and biochemical level remains unresolved.
• No structure of any BAALC-partner complex
• Direct enzymatic versus purely scaffolding role undefined
• Mechanism integrating ERK, MK2a, and adhesion pathways unknown